By Fineline Cube 
US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership with Sanofi (EPA: SAN, NASDAQ: SNY). The French pharmaceutical giant has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases.
Partnership Details
Under the terms of the agreement, Nurix will receive an upfront payment of USD 15 million and is eligible for development, regulatory, and commercial milestone payments totaling up to USD 465 million, along with sales-based royalties.
Historical Collaboration
This expanded collaboration builds on the initial partnership established in 2019, through which Sanofi secured rights to a STAT6 degrader program from Nurix. The ongoing relationship underscores the potential of Nurix’s protein degradation technology in addressing complex therapeutic challenges.-Fineline Info & Tech